ProfileGDS5678 / 1449846_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 45% 47% 48% 49% 57% 45% 46% 48% 68% 49% 26% 49% 52% 52% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.081345
GSM967853U87-EV human glioblastoma xenograft - Control 23.1053447
GSM967854U87-EV human glioblastoma xenograft - Control 33.1454148
GSM967855U87-EV human glioblastoma xenograft - Control 43.1157149
GSM967856U87-EV human glioblastoma xenograft - Control 53.4076157
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1540245
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1492546
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1400248
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.1715968
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1483349
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.5944926
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1442349
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.2706152
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.2714252